/PRNewswire/ BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Medicines Agency (EMA) has granted its request for accelerated.
BioMarin Announces Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study
Children Treated with Vosoritide Demonstrate Cumulative Height Gain of 3.52 cm at Year 2 Compared to Untreated Children
No New Safety Signals Observed
Current Regulatory Review Timelines on Track
News provided by
Share this article
Share this article
SAN RAFAEL, Calif., Dec. 21, 2020 /PRNewswire/ BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that children in the open-label long-term extension of the Phase 3 study of vosoritide, an investigational, once daily injection analog of C-type Natriuretic Peptide (CNP), maintained an increase in Annual Growth Velocity (AGV) through the second year of continuous treatment. These analyses are the result of the combination of data of the same patients enrolled in three consecutive trials. In the first trial, a run in period consisted of longitudinal measurement of height in all